Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Leon Paul Pradel
Observed names:
L. P. Pradel,
Leon P Pradel,
Leon P. Pradel,
Leon Pradel,
Leon P. Pradel
Institution:
Merck Healthcare KGaA, Darmstadt (Germany)
Observed institutions:
University of Salzburg,
Paracelsus Medical University,
Roche Pharma AG (Germany),
Salzburger Landeskliniken,
Merck Healthcare KGaA, Darmstadt (Germany)
OpenAlex ID:
A5111962686
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
2014
·
Carola H. Ries
, Michael A. Cannarile
, et al.
·
Cancer Cell
·
1,480
Fibroblasts Influence Survival and Therapeutic Response in a 3D Co-Culture Model
2015
·
Meher Majety
, Leon P. Pradel
, et al.
·
PLoS ONE
·
135
PDF
Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2016
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
·
Molecular Cancer Therapeutics
·
78
Identification of tumor‐associated macrophage subsets that are associated with breast cancer prognosis
2020
·
Elisabeth Strack
, P. Alexander Rolfe
, et al.
·
Clinical and Translational Medicine
·
51
PDF
Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties
2012
·
R. Castoldi
, U. Jucknischke
, et al.
·
Protein Engineering Design and Selection
·
48
PDF
Effects of IL-10 and Th2 cytokines on human Mφ phenotype and response to CSF1R inhibitor
2018
·
Leon P Pradel
, Andreas Franke
, et al.
·
Journal of Leukocyte Biology
·
8
Figure S4 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Table S1 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Figure S6 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Supplementary information from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Figure S5 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Figure S3 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Figure S1 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Figure S2 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Figure S3 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Figure S2 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Figure S1 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Figure S4 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Figure S5 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Table S1 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Figure S6 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Data from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
Data from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023
·
Leon P. Pradel
, Chia-Huey Ooi
, et al.
ID: 92
2015
·
Leon Paul Pradel
, Carola Ries
·
Cytokine
Abstract PR04: Targeting tumor-asoociated macrophages with a novel anti-CSF1R antibody in cancer patients
2015
·
Michael Cannarile
, Sabine Hoves
, et al.
·
Cancer Research
Show more works
View as search
Works count:
29
Citation count:
1,799
H-index:
6
I10-index:
5
Year
Topic
Type